Our findings regarding the SLE patients are slightly different from previous studies [29,30,31,32], which demonstrated expansion of the effector and senescent CD4+ T- cell subpopulations in SLE patients compared to healthy controls; nevertheless, they emphasize their superiority mainly in patients with active disease, or those with metabolic syndrome. The gene discussed is CD4; the disease is systemic lupus erythematosus.